Skip to main content
TipRanks
Go Ultimate75% OFF

Sana Biotechnology (SANA) Stock Price & Analysis

903 Followers

SANA Stock Chart & Stats

$1.59-$0.15(-8.62%)
At close: 4:00 PM EST
$2$3$4Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.57 - $1.75
52-Week Range
$1.57 - $5.49
Previous Close
$1.74
Volume
N/A
Average Volume (3M)
2.92M
Market Cap
$521.36M
Enterprise Value
$828.47M
Total Cash (Recent Filing)
$121.73M
Total Debt (Recent Filing)
$53.84M
Price to Earnings (P/E)
―
Beta
1.87
Next Earnings
Mar 23, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Losses And Cash Burn

The narrowing loss profile and reduced cash burn indicate improving cost discipline as Sana advances its pipeline. Although the company remains unprofitable, sustained improvement could extend financial runway and reduce the intensity of future capital needs over the next several quarters.

Reduced Leverage

Lower debt and improved leverage provide Sana with a more manageable capital structure for a development-stage biotech. Reduced obligations can limit financing pressure and preserve greater flexibility to direct resources toward clinical development, regulatory preparation, and platform advancement.

Clinical And Pipeline Progress

Clinical validation for UP421 and progress toward an SC451 IND demonstrate advancement beyond purely preclinical research. Durable cell performance and defined regulatory milestones may strengthen the platform’s credibility and create multiple future opportunities for therapeutic development.

Bears Say

No Commercial Revenue

Sana has not yet demonstrated commercial demand or product monetization, so its ability to create shareholder value depends on future clinical success and eventual approvals. Until revenue begins, operating performance remains exposed to development delays and continued reliance on capital resources.

Persistent Cash Burn

Material negative operating and free cash flow means Sana consumes substantial capital while progressing its programs. Continued burn can require external financing or a major revenue step-up, creating funding risk and potentially limiting the pace or breadth of pipeline investment.

Equity Capital Erosion

The large decline in equity reflects prolonged losses consuming the company’s capital base, while deeply negative returns show that current operations are not yet generating economic value. This weakens financial resilience and increases dependence on successful commercialization or additional funding.

Sana Biotechnology News

SANA FAQ

What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.57 and its highest was $5.49 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $521.36M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 122 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 05, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.218.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.17.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 299,634,950 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 1.282%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Hedge funds hold Sana Biotechnology shares: the largest hedge-fund position in Sana Biotechnology is 72,411,788 shares, and hedge funds increased their holdings by 21.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology